Chemotherapy-induced peripheral polyneuropathy in breast cancer patients

Abstract

Breast cancer is the second most common cancer overall, the most common cancer in women, and a leading cause of death in women. The incidence of brain metastases has increased due to longer patient survival. Thus, chemotherapy for breast cancer has significantly increased promising a positive outcome. However, long-term and repeated chemotherapy leads to involvement of the peripheral nervous system by creating clinical issues dominated by peripheral neuropathy and cognitive changes.

This literature review assesses the negative neurological effects of chemotherapy in breast cancer patients.

The review discusses neuropathic pain mechanisms, primarily neuroimmune and inflammatory changes, ion-channel remodeling, mitochondrial dysfunction, and genetic predisposition. The review gives advice on the prevention of peripheral neuropathy and neuropathic pain in breast cancer patients. It shows the relationship of chemotherapy and deteriorated quality of life, where special attention should be paid to early detection and treatment of chemotherapy-induced peripheral polyneuropathy to improve the quality of life of breast cancer patients.

With advances in pharmacology, the introduction of targeted therapy and its combinations, especially those involving epidermal growth factor receptor 2, the survival potential of breast cancer patients increases, but there are risks of more frequent neurological complications, primarily peripheral neuropathy and cognitive changes.

Keywords

breast cancer / chemotherapy / polyneuropathy

References

[1] Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359-386. doi: 10.1002/ijc.29210

[2] Ferlay J., Soerjomataram I., Dikshit R., et. al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012 // Int J Cancer. 2015. Vol 136, N 5. P. E359–386. doi: 10.1002/ijc.29210

[3] Chew S, Carroll HK, Darwish W, et al. Characterization of treatments and disease course for women with breast cancer brain metastases: 5-year retrospective single institution experience. Cancer Manag Res. 2021;13:8191–8198. doi: 10.2147/CMAR.S330829

[4] Chew S., Carroll H.K., Darwish W., et al. Characterization of treatments and disease course for women with breast cancer brain metastases: 5-year retrospective single institution experience // Cancer Manag Res. 2021. Vol. 13. P. 8191–8198. doi: 10.2147/CMAR.S330829

[5] Kim HJ, Im SA, Keam B, et al. Clinical outcome of central nervous system metastases from breast cancer: differences in survival depending on systemic treatment. J Neurooncol. 2012;106(2):303–313. doi: 10.1007/s11060-011-0664-8

[6] Kim H.J., Im S.A., Keam B., et al. Clinical outcome of central nervous system metastases from breast cancer: differences in survival depending on systemic treatment // J Neurooncol. 2012. Vol. 106, N 2. P. 303–313. doi: 10.1007/s11060-011-0664-8

[7] Avila J, Leone JP. Advances in the management of central nervous system metastases from breast cancer. Int J Mol Sci. 2022;23(20):12525. doi: 10.3390/ijms232012525

[8] Avila J., Leone J.P. Advances in the management of central nervous system metastases from breast cancer // Int J Mol Sci. 2022. Vol. 23, N 20. P. 12525. doi: 10.3390/ijms232012525

[9] Mustafa Ali M, Moeller M, Rybicki L, et al. Long-term peripheral neuropathy symptoms in breast cancer survivors. Breast Cancer Res Treat. 2017;166(2):519–526. doi: 10.1007/s10549-017-4437-8

[10] Mustafa Ali M., Moeller M., Rybicki L., Moore H.C.F . Long-term peripheral neuropathy symptoms in breast cancer survivors // Breast Cancer Res Treat. 2017. Vol. 166, N 2. P. 519–526. doi: 10.1007/s10549-017-4437-8

[11] Bao T, Basal C, Seluzicki C, et al. Long-term chemotherapy-induced peripheral neuropathy among breast cancer survivors: prevalence, risk factors, and fall risk. Breast Cancer Res Treat. 2016;159(2):327–333. doi: 10.1007/s10549-016-3939-0

[12] Bao T., Basal C., Seluzicki C., et al. Long-term chemotherapy-induced peripheral neuropathy among breast cancer survivors: prevalence, risk factors, and fall risk // Breast Cancer Res Treat. 2016. Vol. 159, N 2. P. 327–333. doi: 10.1007/s10549-016-3939-0

[13] Kolb NA, Smith AG, Singleton JR, et al. The association of chemotherapy-induced peripheral neuropathy symptoms and the risk of falling. JAMA Neurol. 2016;73(7):860–866. doi: 10.1001/jamaneurol.2016.0383

[14] Kolb N.A., Smith A.G., Singleton J.R., et al. The association of chemotherapy-induced peripheral neuropathy symptoms and the risk of falling // JAMA Neurol. 2016. Vol. 73, N 7. P. 860–866. doi: 10.1001/jamaneurol.2016.0383

[15] Ewertz M, Qvortrup C, Eckhoff L. Chemotherapy-induced peripheral neuropathy in patients treated with taxanes and platinum derivatives. Acta Oncol. 2015;54(5):587–591. doi: 10.3109/0284186X.2014.995775

[16] Ewertz M., Qvortrup C., Eckhoff L. Chemotherapy-induced peripheral neuropathy in patients treated with taxanes and platinum derivatives // Acta Oncol. 2015. Vol 54, N 5. P. 587–591. doi: 10.3109/0284186X.2014.995775

[17] Molassiotis A, Cheng HL, Leung KT, et al. Risk factors for chemotherapy-induced peripheral neuropathy in patients receiving taxane- and platinum-based chemotherapy. Brain Behav. 2019;9(6):e01312. doi: 10.1002/brb3.1312

[18] Molassiotis A., Cheng H.L., Leung K.T., et al. Risk factors for chemotherapy-induced peripheral neuropathy in patients receiving taxane- and platinum-based chemotherapy // Brain Behav. 2019. Vol. 9, N 6. P. e01312. doi: 10.1002/brb3.1312

[19] Koyanagi M, Imai S, Nakagawa T, et al. [Identification of biomarkers and new therapies for taxane-induced peripheral neuropathy]. Nihon Yakurigaku Zasshi. 2019;154(5):241–244. (Japanese). doi: 10.1254/fpj.154.241

[20] Koyanagi M., Imai S., Nakagawa T., et al. Identification of biomarkers and new therapies for taxane-induced peripheral neuropathy // Nihon Yakurigaku Zasshi. 2019. Vol. 154, N 5. P. 241–244. doi: 10.1254/fpj.154.241

[21] Andersen Hammond E, Pitz M, Shay B. Neuropathic pain in taxane-induced peripheral neuropathy: evidence for exercise in treatment. Neurorehabil Neural Repair. 2019;33(10):792–799. doi: 10.1177/1545968319860486

[22] Andersen Hammond E., Pitz M., Shay B. Neuropathic pain in taxane-induced peripheral neuropathy: evidence for exercise in treatment // Neurorehabil Neural Repair. 2019. Vol. 33, N 10. P. 792–799. doi: 10.1177/1545968319860486

[23] Rivera DR, Ganz PA, Weyrich MS, et al. Chemotherapy-associated peripheral neuropathy in patients with early-stage breast cancer: a systematic review. J Natl Cancer Inst. 2018;110(2):djx140. doi: 10.1093/jnci/djx140

[24] Rivera D.R., Ganz P.A., Weyrich M.S., et al. Chemotherapy-associated peripheral neuropathy in patients with early-stage breast cancer: a systematic review // J Natl Cancer Inst. 2018. Vol. 110, N 2. P. djx140. doi: 10.1093/jnci/djx140

[25] Salehifar E, Janbabaei G, Alipour A, et al. Taxane-induced peripheral neuropathy and quality of life in breast cancer patients. J Oncol Pharm Pract. 2020;26(6):1421–1428. doi: 10.1177/1078155219898511

[26] Salehifar E., Janbabaei G., Alipour A., et al. Taxane-induced peripheral neuropathy and quality of life in breast cancer patients // J Oncol Pharm Pract. 2020. Vol. 26, N 6. P. 1421–1428. doi: 10.1177/1078155219898511

[27] Song SJ, Min J, Suh SY, et al. Incidence of taxane-induced peripheral neuropathy receiving treatment and prescription patterns in patients with breast cancer. Support Care Cancer. 2017;25(7):2241–2248. doi: 10.1007/s00520-017-3631-x

[28] Song S.J., Min J., Suh S.Y. Incidence of taxane-induced peripheral neuropathy receiving treatment and prescription patterns in patients with breast cancer // Support Care Cancer. 2017. Vol. 25, N 7. P. 2241–2248. doi: 10.1007/s00520-017-3631-x

[29] Atkins SLP, Zimmer AS. Neurologic complications of breast cancer. Cancer. 2023;129(4):505–520. doi: 10.1002/cncr.34518

[30] Atkins S.L.P., Zimmer A.S. Neurologic complications of breast cancer // Cancer. 2023. Vol. 129, N 4. P. 505–520. doi: 10.1002/cncr.34518

RIGHTS & PERMISSIONS

Eco-Vector